GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (NAS:KTRA) » Definitions » ROC (Joel Greenblatt) %

Kintara Therapeutics (Kintara Therapeutics) ROC (Joel Greenblatt) % : -585.21% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Kintara Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Kintara Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -585.21%.

The historical rank and industry rank for Kintara Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

KTRA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -407200   Med: -23642.94   Max: -1104.97
Current: -1104.97

During the past 13 years, Kintara Therapeutics's highest ROC (Joel Greenblatt) % was -1104.97%. The lowest was -407200.00%. And the median was -23642.94%.

KTRA's ROC (Joel Greenblatt) % is ranked worse than
68.44% of 1470 companies
in the Biotechnology industry
Industry Median: -339.53 vs KTRA: -1104.97

Kintara Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Kintara Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Kintara Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics ROC (Joel Greenblatt) % Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -407,200.00 -28,384.21 -18,901.67 -3,703.63

Kintara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,094.29 -975.12 -1,659.98 -1,688.95 -585.21

Competitive Comparison of Kintara Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Kintara Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's ROC (Joel Greenblatt) % falls into.



Kintara Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.567) - (3.336 + 0 + 0)
=-2.769

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.103 + 0 + 0.114) - (1.87 + 0 + 0)
=-1.653

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Kintara Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.076/( ( (0.694 + max(-2.769, 0)) + (0.699 + max(-1.653, 0)) )/ 2 )
=-4.076/( ( 0.694 + 0.699 )/ 2 )
=-4.076/0.6965
=-585.21 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kintara Therapeutics  (NAS:KTRA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Kintara Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (Kintara Therapeutics) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Executives
Robert Hoffman director, officer: President and CEO ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Anthony Scott Praill officer: Chief Financial Officer 2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3
Saiid Zarrabian director, officer: Head of Strategic Partnerships P.O. BOX 675765, RANCHO SANTA FE CA 92067
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Toth Robert Joseph Jr director 543 LOMBARD ST, SAN FRANCISCO CA 94133
Dennis M Brown officer: Chief Scientific Officer 100 SAN MATEO DR, MENLO PARK CA 94025
Keith Murphy director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
John Liatos director, officer: SVP, Business Development 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
John K Bell director 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8
Napoleone Ferrara director 550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101
Lynda Sarah Cranston director 4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3
Erich Mohr director 8300 GREENSBORO DRIVE, MCLEAN VA 22102
Jeffrey Bacha director SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010